United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2014_register executive 2014-12-09 article Notices D09002ee1c7f82ae5 D09002ee1c7f82b5b United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Evaluation Option License Agreement to BioIntervene, Inc., a company having a place of business in Saint Louis, Missouri to practice the inventions embodied in the following patent applications and patents: 1. U.S. Patent 8,735,407, issued May 27, 2014, titled "Purine Derivatives As A3 Adenosine Receptor-Selective Agonists" [HHS Ref. No. E-140-2008/0-US-06]; 2. European Patent Application 09728154.7, filed March 24, 2009, titled "Purine Derivatives As A3 Adenosine Receptor-Selective Agonists" [HHS Ref. No. E-140-2008/0-EP-05]; 3. Canadian Patent Application 2720037, filed March 24, 2009, titled "Purine Derivatives As A3 Adenosine Receptor-Selective Agonists" [HHS Ref. No. E-140-2008/0-CA-04]; 4. Australian Patent 2009231978, issued February 20, 2014, titled "Purine Derivatives As A3 Adenosine Receptor-Selective Agonists" [HHS Ref. No. E-140-2008/0-AU-03]; 5. U.S. Patent Application 13/371,081, filed February 10, 2012, titled "A3 Adenosine Receptor Agonists And Antagonists" [HHS Ref. No. E-140-2008/1-US-01]; 6. U.S. Provisional Application 61/909,742, filed November 27, 2013, titled "A3 Adenosine Receptor Agonists" [HHS Ref. No. E-742- 2013/0-US-01]; and 7. U.S. Provisional Application 62/033,723, filed August 6, 2014, titled "A3 Adenosine Receptor Agonists" [HHS Ref. No. E-210-2014/0- US-01]. The patent rights in these inventions either have been assigned to the Government of the United States of America, or have been granted exclusive rights to the Government of the United States of America. The territory of the prospective Start-up Exclusive Evaluation Option License Agreement may be worldwide, and the field of use may be limited to: "The use of an A3 Adenosine Receptor (A3AR) agonist as an orally- administered analgesic, either as monotherapy or as an add-on analgesic, for treatment of chronic neuropathic pain conditions". Upon the expiration or termination of the Start-up Exclusive Evaluation Option License Agreement, BioIntervene will have the exclusive right to execute a Start-up Exclusive Patent License Agreement which will supersede and replace the Start-up Exclusive Evaluation Option License Agreement, with no greater field of use and territory than granted in the Start-up Exclusive Evaluation Option License Agreement. 79 FR 73091 https://www.govinfo.gov/app/details/FR-2014-12-09/2014-28749 2014-28749 fr09de14-73 4140-01-P https://www.govinfo.gov/app/details/FR-2014-12-09/2014-28749 https://www.govinfo.gov/content/pkg/FR-2014-12-09/html/2014-28749.htm https://www.govinfo.gov/content/pkg/FR-2014-12-09/pdf/2014-28749.pdf 2 p. 73091 73092 79 FR 73091 Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: A3 Adenosine Receptor (A3AR) Agonists as an Orally-Administered Analgesic for Treatment of Chronic Neuropathic Pain; Federal Register Vol. 79, Issue NOTICE 2014-28749 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2014-12-24 4140-01-P 2014-28749 Notice

This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Evaluation Option License Agreement to BioIntervene, Inc., a company having a place of business in Saint Louis, Missouri to practice the inventions embodied in the following patent applications and patents: 1. U.S. Patent 8,735,407, issued May 27, 2014, titled "Purine Derivatives As A3 Adenosine Receptor-Selective Agonists" [HHS Ref. No. E-140-2008/0-US-06]; 2. European Patent Application 09728154.7, filed March 24, 2009, titled "Purine Derivatives As A3 Adenosine Receptor-Selective Agonists" [HHS Ref. No. E-140-2008/0-EP-05]; 3. Canadian Patent Application 2720037, filed March 24, 2009, titled "Purine Derivatives As A3 Adenosine Receptor-Selective Agonists" [HHS Ref. No. E-140-2008/0-CA-04]; 4. Australian Patent 2009231978, issued February 20, 2014, titled "Purine Derivatives As A3 Adenosine Receptor-Selective Agonists" [HHS Ref. No. E-140-2008/0-AU-03]; 5. U.S. Patent Application 13/371,081, filed February 10, 2012, titled "A3 Adenosine Receptor Agonists And Antagonists" [HHS Ref. No. E-140-2008/1-US-01]; 6. U.S. Provisional Application 61/909,742, filed November 27, 2013, titled "A3 Adenosine Receptor Agonists" [HHS Ref. No. E-742- 2013/0-US-01]; and 7. U.S. Provisional Application 62/033,723, filed August 6, 2014, titled "A3 Adenosine Receptor Agonists" [HHS Ref. No. E-210-2014/0- US-01]. The patent rights in these inventions either have been assigned to the Government of the United States of America, or have been granted exclusive rights to the Government of the United States of America. The territory of the prospective Start-up Exclusive Evaluation Option License Agreement may be worldwide, and the field of use may be limited to: "The use of an A3 Adenosine Receptor (A3AR) agonist as an orally- administered analgesic, either as monotherapy or as an add-on analgesic, for treatment of chronic neuropathic pain conditions". Upon the expiration or termination of the Start-up Exclusive Evaluation Option License Agreement, BioIntervene will have the exclusive right to execute a Start-up Exclusive Patent License Agreement which will supersede and replace the Start-up Exclusive Evaluation Option License Agreement, with no greater field of use and territory than granted in the Start-up Exclusive Evaluation Option License Agreement.

Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before December 24, 2014 will be considered. Prospective Grants of Start-Up Exclusive Evaluation Option License Agreements: A3 Adenosine Receptor Agonists as an Orally-administered Analgesic for Treatment of Chronic Neuropathic Pain , tongb@mail.nih.gov Vol. 79, no. 236 Office of the Federal Register, National Archives and Records Administration 2014-12-09 continuing daily deposited born digital 234 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2014-12-09 P0b002ee18a6e0db7 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr09de14 https://www.govinfo.gov/app/details/FR-2014-12-09 https://www.govinfo.gov/content/pkg/FR-2014-12-09/pdf/FR-2014-12-09.pdf https://www.govinfo.gov/content/pkg/FR-2014-12-09/xml/FR-2014-12-09.xml fdlp 72967 73190 DGPO 2014-12-09 2024-06-02 FR-2014-12-09 machine generated eng FR FR-2014-12-09 79 236